Ignite Creation Date:
2024-05-05 @ 6:38 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00510276
Status:
COMPLETED
Last Update Posted:
2010-04-14
First Post:
2007-07-30
Brief Title:
Treatment of Attention-DeficitHyperactivity Disorder ADHD With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Double-Blind Study of Atomoxetine Hydrochloride Versus Placebo for the Treatment of ADHD in Young Adults With an Assessment of Associated Functional Outcomes
Status:
COMPLETED
Status Verified Date:
2010-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate atomoxetines efficacy in treating attention-deficithyperactivity disorder ADHD symptoms and atomoxetines effect on functional outcomes in young adults
A gatekeeper strategy will be employed for sequentially testing the secondary objectives
This study also has an observational community sample arm in which patients will complete all the efficacy measurements via web-based self reporting
A gatekeeper strategy will be employed for sequentially testing the secondary objectives
This study also has an observational community sample arm in which patients will complete all the efficacy measurements via web-based self reporting
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| B4Z-US-LYDZ | OTHER | Eli Lilly and Company | None |